===
Guerbet
Guerbet: Change in Guerbet's Board of Directors.
20-March-2024 / 18:00 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Change in Guerbet's Board of Directors


Villepinte, 20 March 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical
imaging, today appointed Hugues Lecat as "Censeur" (non-voting director) with immediate effect.
Hugues Lecat's appointment as a director will be submitted for approval at the next Shareholders' Meeting. Following
that General Meeting, a proposal will be made to the Board of Directors of Guerbet to appoint Hugues Lecat as Chairman
of the board, replacing Didier Izabel (who will remain a director and Chairman of the Audit Committee until the end of
his term of office of Director in 2026).
Eric Guerbet (director and secretary of the Shareholders' Agreement between members of the Guerbet family) on behalf of
all the Group's directors:
"The members of the Board of Directors are delighted that Hugues Lecat has agreed to join the Guerbet Group as
"Censeur" with the goal of becoming a director and subsequently Chairman of the board of the company, subject to
approval by the Shareholders' Meeting. The management experience acquired by Hugues in large companies in the
pharmaceutical sector will help guide the Group in achieving further success. His understanding of governance issues
and his strategic vision will be valuable assets in an international environment that offers many development
opportunities. Together with the representatives of the Guerbet family, the majority shareholder, Hugues Lecat will
share their high ambitions for the Group, while safeguarding the interests of all shareholders. Hugues Lecat and David
Hale, CEO of Guerbet, will complement each other perfectly as they work together to strengthen Guerbet's positions as a
leader in France, Europe and worldwide in diagnostic and interventional imaging for patients and healthcare
professionals."
Hugues Lecat:
"I am thrilled to join the Board of Directors of Guerbet and to have the opportunity to subsequently take over as its
Chairman, subject to the agreement of its shareholders, and I would like to thank the members of the Board of Directors
for their trust. I am very excited at the prospect of contributing to the future success of the Group. David Hale can
count on my full support in developing the roadmap and implementing strategies that will strengthen our market position
and drive long-term sustainable growth."

Biography

Hugues Lecat is a graduate of the NEOMA business school in Rouen and holds an MBA from INSEAD. He began his career in
the pharmaceutical sector at Medtronic France in the mid-1990s, where he quickly demonstrated his skills in business
development and financial management. In 1999, Hugues moved to the commercial operations arm of Aventis Pharma France,
where he was Chief Financial Officer for four years. He subsequently held several senior management positions,
including CEO of Théraplix, a subsidiary of Aventis Pharma specialising in pain treatment and OTC products, and CEO of
Sanofi-Aventis OTC. In 2009, Hugues became CEO of Cooper Consumer Health, before joining Ethypharm in 2010. As its
Chairman and CEO, Hugues transformed Ethypharm from its original focus on galenic development into an international
pharmaceutical group focused on the central nervous system and injectable products for hospitals. He has been Chairman
of the Supervisory Board since 2019. Hugues was also a member of the Board of Directors of NOVASEP on behalf of BPI
between 2012 and 2017.

Next event:

Investor presentation
21 March 2024

Publication of 1st quarter 2024 revenue
25 April 2024 after market close



About Guerbet
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a
leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and
digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more
than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in
four centres in France, in United States and Israël. Guerbet (GBT) is listed on Euronext Paris (segment B-mid caps) and
generated EUR786 million in revenue in 2023.
Contacts:
Guerbet
Jérôme Estampes, Chief Financial Officer +33 1 45 91 50 00 / jerome.estampes@guerbet.com
Christine Allard, Head of Communications +33 6 30 11 57 82 / christine.allard@guerbet.com
Actifin
Marianne Py, Financial Communications +33 1 80 48 25 31 / marianne.py@seitosei-actifin.com
Jennifer Jullia, Press +33.1.56.88.11.19 / jennifer.jullia@seitosei-actifin.com

Regulatory filing PDF file

File: GUERBET_evolutionCA_20032024VdefEN  
Language:        English 
Company:         Guerbet 

Zone Paris Nord II 15 Rue des Vanesses
93420 Villepinte
France

Internet:        https://www.guerbet.com/investors 
ISIN:            FR0000032526 

Euronext Ticker: GBT

AMF Category:    Inside information / Other releases 
EQS News ID:     1863561 

End of Announcement EQS News Service
===
1863561 20-March-2024 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1863561&application_name=news

END) Dow Jones Newswires

March 20, 2024 13:00 ET (17:00 GMT)